nab-Sirolimus Plus Letrozole in Advanced or Recurrent Endometrioid Endometrial Cancer: A Phase 2, Open-Label, Single-Arm, Prospective, Multicenter Study

Home nab-Sirolimus Plus Letrozole in Advanced or Recurrent Endometrioid Endometrial Cancer: A Phase 2, Open-Label, Single-Arm, Prospective, Multicenter Study

nab-Sirolimus Plus Letrozole in Advanced or Recurrent Endometrioid Endometrial Cancer: A Phase 2, Open-Label, Single-Arm, Prospective, Multicenter Study

nab-Sirolimus Plus Letrozole in Advanced or Recurrent Endometrioid Endometrial Cancer: A Phase 2, Open-Label, Single-Arm, Prospective, Multicenter Study

/ Publications

Share the Post

About the Author

AadiSite Support

Related Posts

Aadi Bioscience to Participate in Upcoming Investor Conferences
Read More
Bryan Ball
Response to Treatment With nab-Sirolimus Among Patients With Malignant PEComa of Uterine Origin: A Subanalysis From AMPECT 
Read More
Anupam Dalal, MD
Aadi Bioscience Announces Collaborations with Next Generation Sequencing Leaders
Aadi Bioscience to Present at the H.C. Wainwright Global Investment Conference
PRECISION 1: A phase 2, multicenter, open-label tumor-agnostic trial of nab-sirolimus for malignant solid tumors harboring pathogenic inactivating alterations in TSC1 and TSC2
Aadi Bioscience Announces Preliminary Data for FYARRO™ in Patients with Solid Tumors Harboring TSC1 and TSC2 Alterations from a Multi-Institution Expanded Access Study to be Presented at ASCO 2021 Virtual Meeting

Comments

Comments are closed.